Skip to main content
Preview

Research from Friday’s close · next update overnight after Monday’s close

Sagehood30
PFE

PFE Research brief

Pfizer

Adjusted close as of 2026-10-30
$30.52(+1.90%)

Sagehood’s view on PFE

Pfizer · Research 2026-10-30 · Accepted

Research score

58Neutral50 is balancedScore change +2 since 2026-10-29, from 56 to 58; view unchanged at Neutral. Compare the two recordsConfidence 65 · It is not a calibrated probability of investment success.Confidence across the 100 names in this research run: 45 to 70, median 55.
How to read this score

In Sagehood30 · book 2026-10-30

Dated research brief

WhyPFE looks neutral because the tape is strong while the fundamentals are flat. The unresolved risk is that the base fair value of $18.3 sits 40% below the $30.52 close.
What argues against this viewThe strongest case against the neutral view is that the modeled value sits far below the traded price.
Break conditionFrom the financial specialist: A later reading showing trailing-twelve-month revenue growth above the threshold of 0 would break the flat-revenue claim, since the current figure is negative 0.2%.Tests that specialist’s reading, not this page’s whole Neutral view.

Sagehood does not check this condition automatically. See research limitations below.

Valuation range

Close vs. model fair value · discounted cash flow

Bear
$12.30
Base
$18.30
Bull
$33.90

Base case −40% vs. the 2026-10-30 close, on fundamentals to 2026-06-28. Peer-implied median $35.01 from 3 peer-median multiples. Estimates from this research’s valuation model, not a price target.

The market price implies more growth or higher margins than this model assumes, so its base case sits far below the close. The valuation specialist weighs that gap; it is not a forecast that the price will fall.

Against peers

Health Care
MultiplePFEGroup medianPercentile
P/E (TTM)40.16×20.39×75th
P/S2.75×3.15×33rd
P/B2.05×3.99×17th
FCF yield6.28%5.36%67th
Score details & research limitations9 unavailable fields
Conditions Sagehood can check on its ownNot available in this run. A written break condition is not an automated check; this run does not provide a source-linked rule Sagehood can verify on its own.

Where the break condition comes from: Sagehood research took this condition from the financial specialist. It tests that specialist’s own reading, so it does not say everything that would change this page’s Neutral view.

How to read this research

The score expresses the published research view. 50 is balanced.

Bullish, Neutral or Bearish beside the score is the direction of that view, set by the research from the score: 65 and above is Bullish, 45 to 64 Neutral, 44 and below Bearish.

Confidence is how well the evidence supports this view, not which way it points: Sagehood research is asked to keep it no higher than its most confident specialist, and lower when the specialists disagree or much of the evidence is weak. It is not a calibrated probability of investment success.

Source verification checks the identity and origin of evidence. It does not prove that a claim is correct or that an investment will succeed.

Valuation estimates depend on their inputs and assumptions. They are not guaranteed future prices.

Retrospective research looks back at an earlier period. It is not a verified record of a decision made then using only information available then.

Unavailable is not zero. Read the adjacent reason: information may be missing, unverified or deliberately withheld.

How Sagehood works

The session this view is fixed to

Close$30.52 on 2026-10-30, as the research recorded it
Change on the day+1.90%
First eligible market session2026-11-02

Recorded score context

Specialist source coverage8 of 10 specialists have a verified source on this run. 2 do not.
Score reconciliationThe 8 specialist contributions shown add up to the weighted starting point this score was built from.
Change since the last accepted run56 on 2026-10-29 → 58 on 2026-10-30 (+2 points). This is simple arithmetic between the two published scores, not an explanation of the change.
The run this is compared withResearch of 2026-10-29

Not in this run: Run-specific score definition, Confidence band, Horizon, Why the score changed, Today's unexplained move and Blockers.

What this was built from

Filing cited in the evidenceNot recorded on this card. The newest filing on record is under Key financials, and recent filings are listed under SEC filings.
Peer set6 names in Health Care: BMY, BSX, MDT, MRK, MRNA, VTRS. How they were chosen is under “Valuation & peers”. The valuation range shows the peer-implied median from 3 peer-median multiples.

Not in this run: Company profile date and Standing disclosure.

Not available in this run

9 fields are unavailable. Each is identified with its reason above; missing information is not zero or a negative research signal.

Price context

· adjusted close $30.52

+31.2% from 2026-06-25

Recent price-basis check: 2026-10-02 to 2026-10-30 (20 sessions). Economic comparability outside this window remains unchecked.

PFE adjusted close
Adjusted price · USD · viewing 2026-06-25 to 2026-10-30

Selected 2026-10-30. PFE adjusted close. Continuous series. $30.52 US dollars.

90 daily adjusted-price observations through 2026-10-30, ending at the 2026-10-30 research date. The final point is a dated final close. Shown for context, not point-in-time research evidence: the research used the prices recorded with it.

Use the arrow keys on the chart to step through observations.

Published score history

2026-07-23 to 2026-10-30 · 37 publications

Each point is a verified published score. The line breaks where the research method changed (4 methods, numbered in the order they were first used), so scores are not joined across methods. Hollow points were published after their decision window (retrospective).

Every published score and confidence
Research dateScoreViewConfidenceMethod
2026-10-3058Neutral65Method 4
2026-10-2956Neutral55Method 4
2026-10-2854Neutral50Method 4
2026-10-2754Neutral50Method 4
2026-10-2657Neutral60Method 4
2026-10-2358Neutral60Method 4
2026-10-2260Neutral62Method 4
2026-10-2158Neutral55Method 4
2026-10-1660Neutral58Method 4
2026-10-0955Neutral50Method 4
2026-10-0757Neutral55Method 4
2026-10-0254Neutral60Method 4
2026-10-0157Neutral58Method 4
2026-09-3055Neutral55Method 4
2026-09-2955Neutral65Method 4
2026-09-2856Neutral70Method 4
2026-09-2554Neutral60Method 4
2026-09-24 · retrospective54Neutral55Method 4
2026-09-2355Neutral60Method 4
2026-09-1856Neutral55Method 4
2026-09-16 · retrospective52Neutral50Method 4
2026-09-09 · retrospective53Neutral55Method 4
2026-09-0452Neutral55Method 4
2026-09-01 · retrospective56Neutral60Method 4
2026-08-31 · retrospective51Neutral70Method 3
2026-08-2854Neutral59Method 3
2026-08-26 · retrospective50Neutral69Method 3
2026-08-24 · retrospective54Neutral59Method 3
2026-08-20 · retrospective55Neutral59Method 3
2026-08-19 · retrospective51Neutral69Method 3
2026-08-1457Neutral61Method 2
2026-08-1358Neutral61Method 1
2026-08-0758Neutral61Method 1
2026-08-0658Neutral61Method 1
2026-08-0457Neutral62Method 1
2026-07-3153Neutral65Method 1
2026-07-2350Neutral53Method 1

Specialists

8 of 10 published specialist analyses are available.

Each specialist’s view is shown as the published research recorded it; supporting detail appears only when it was recorded with that same view.

2 unavailable

PFE research

Financial specialist

Showing Financial specialist result.

Financial specialist

Evaluated for this session

Neutral

Pfizer's revenue is flat at negative 0.2% trailing-twelve-month growth versus the 4.6% sector revenue-growth median, though it still converts $13,401 million of operating cash flow into $10,985 million of free cash flow. Leverage comparisons are not available.

Full analyst note

What the specialist sees

Evidence: trailing-twelve-month revenue was $63,696 million with negative 0.2% growth against the 4.6% sector revenue-growth median, trailing-twelve-month free cash flow was $10,985 million on $13,401 million of operating cash flow, and the facts' period ends 2026-06-28.

Why it matters now

Free cash flow of $10,985 million on $13,401 million of operating cash flow supports cash generation, while revenue growth of negative 0.2% trails the 4.6% sector revenue-growth median and the missing net-debt-to-EBITDA and interest-coverage comparisons leave leverage unconfirmed.

What could change the view

Countercase: The 10-Q filed on 2026-08-04 is not yet reflected in these facts, and net debt to EBITDA and interest coverage are not available, so the leverage read rests on debt principal alone. Falsifier: A later reading showing trailing-twelve-month revenue growth above the threshold of 0 would break the flat-revenue claim, since the current figure is negative 0.2%.

Specialist score details
Specialist score
58
Evidence confidence
50
Base weight for this role
0.13
Base weight × confidence
6.50
Weight in the score (the chip's weight)
0.13
Weighted contribution
7.70
Business driver
Trailing-twelve-month revenue was $63,696 million with negative 0.2% growth against the 4.6% sector revenue-growth median, trailing-twelve-month free cash flow was $10,985 million on $13,401 million of operating cash flow, and the facts' period ends 2026-06-28.
Mechanism
Free cash flow of $10,985 million on $13,401 million of operating cash flow supports cash generation, while revenue growth of negative 0.2% trails the 4.6% sector revenue-growth median and the missing net-debt-to-EBITDA and interest-coverage comparisons leave leverage unconfirmed.
Countercase
The 10-Q filed on 2026-08-04 is not yet reflected in these facts, and net debt to EBITDA and interest coverage are not available, so the leverage read rests on debt principal alone.
Contributions & coverage details

Specialist contributions

Each specialist’s recorded numbers, in the usual specialist order, as recorded: nothing is re-ranked or recalculated. Weights and contributions show two decimals; hover for the exact value.

Financial specialist

Neutral

Score
58
Evidence confidence
50
Weight in the score
0.13
Weighted contribution
7.70

Risk specialist

Neutral

Score
55
Evidence confidence
55
Weight in the score
0.09
Weighted contribution
4.94

Sector specialist

Neutral

Score
58
Evidence confidence
60
Weight in the score
0.12
Weighted contribution
7.10

SEC filings specialist

Neutral

Score
50
Evidence confidence
58
Weight in the score
0.04
Weighted contribution
1.78

News specialist

Neutral

Score
50
Evidence confidence
45
Weight in the score
0.10
Weighted contribution
5.05

Price-trend specialist

Bullish

Score
72
Evidence confidence
75
Weight in the score
0.31
Weighted contribution
22.05

Valuation specialist

Bearish

Score
38
Evidence confidence
35
Weight in the score
0.11
Weighted contribution
4.34

Economy specialist

Neutral

Score
54
Evidence confidence
60
Weight in the score
0.10
Weighted contribution
5.29

Published specialist analyses unavailable: Geopolitics specialist, Social-media specialist. No specialist result is inferred.

  • Geopolitics specialist: This specialist had no checked public source on this run, so no source-backed analysis is shown.
  • Social-media specialist: This specialist had no checked public source on this run, so no source-backed analysis is shown.

How this insight was formed

Each specialist view shown here is checked against the published research files. Sagehood research combined those views into the one Research Score above.

Evidence & method

Inspect the reasoning, source records and valuation behind this dated view.

Sagehood research reasoningSpecialist reasoning, selected statements and filing context
Accepted publication2026-10-30 researchNext eligible session 2026-11-02point-in-time

PFE: Sagehood research reasoning

Accepted research score

58

Neutral50 is balanced
Lead specialist in the research decision:

Financial specialist

Neutral

Specialist score 58Evidence confidence 50
What the specialist sees

Trailing-twelve-month revenue was $63,696 million with negative 0.2% growth against the 4.6% sector revenue-growth median, trailing-twelve-month free cash flow was $10,985 million on $13,401 million of operating cash flow, and the facts' period ends 2026-06-28.

Why it matters

Free cash flow of $10,985 million on $13,401 million of operating cash flow supports cash generation, while revenue growth of negative 0.2% trails the 4.6% sector revenue-growth median and the missing net-debt-to-EBITDA and interest-coverage comparisons leave leverage unconfirmed.

What argues against it

The 10-Q filed on 2026-08-04 is not yet reflected in these facts, and net debt to EBITDA and interest coverage are not available, so the leverage read rests on debt principal alone.

This specialist’s break condition: A later reading showing trailing-twelve-month revenue growth above the threshold of 0 would break the flat-revenue claim, since the current figure is negative 0.2%.

How the score was formed

The specialists’ weighted starting point was 58.25. Sagehood research’s adjustment was −0.25. 56 on 2026-10-29 → 58 on 2026-10-30 (+2 points). This is simple arithmetic between the two published scores, not an explanation of the change.

Evidence Sagehood research weighed

These selected claims are evidence Sagehood research weighed, not a reconstruction of the numeric adjustment.

Claims as this research published them. Sagehood confirms each claim and its support were published together with this research. That is not an independent check, and it does not prove the claim is accurate or predict future performance.

  1. Financial specialist

    Same statement as under “What the specialist sees” above.

  2. Price-trend specialist

    PFE closed at $30.52 on 2026-10-30, at its 52-week high and 4.9% above the $29.02 support (1 touch); the 1-year channel slope is 17.5% per year with fit R² 0.5 and trend-channel position 1.9 standard deviations, while the 90-day channel slope is 101.1% per year with fit R² 0.87.

  3. Valuation specialist

    The base case pairs −5% revenue growth with a 17.2% FCF margin for a $18.3 fair value, 40% below the $30.52 close, while the bear case at a 13.2% margin gives $12.3, 60% below.

Sagehood research decision

The investment case, main risk and break condition are the ones shown under Sagehood’s view at the top of this page.

Recorded break condition
Break condition as kept in the decision trail

A later reading showing TTM revenue growth above the threshold of 0 would break the flat-revenue claim, since the current figure is negative 0.2%.

Evidence & sourcesClaim-support availability, filing-context links and research method

PFE: This run has no checked links from its claims to their evidence. The specialists’ writing is shown as recorded, and no missing evidence is filled in.

Research evidence at a glance

Accepted specialist evidence · no score adjustment

Key figures

Fundamentals

Trailing-twelve-month revenue was $63,696 million with negative 0.2% growth against the 4.6% sector revenue-growth median, trailing-twelve-month free cash flow was $10,985 million on $13,401 million of operating cash flow, and the facts' period ends 2026-06-28.

Valuation model

The base case pairs −5% revenue growth with a 17.2% FCF margin for a $18.3 fair value, 40% below the $30.52 close, while the bear case at a 13.2% margin gives $12.3, 60% below.

Potential upside

  • Pfizer's revenue is flat at negative 0.2% trailing-twelve-month growth versus the 4.6% sector revenue-growth median, though it still converts $13,401 million of operating cash flow into $10,985 million of free cash flow. Leverage comparisons are not available.

Potential downside

  • Base fair value of $18.3 is 40% below the $30.52 close, with the bear case at $12.3 (−60%) and the bull at $33.9 (+11%).

Questions to watch

  • A later reading showing trailing-twelve-month revenue growth above the threshold of 0 would break the flat-revenue claim, since the current figure is negative 0.2%.

  • A later reading showing the FCF margin rising above 21.2% would break the bearish case, since that column's $24.4 fair value sits 20% under the close.

Accepted research

Research dated 2026-10-30.

How this research was made

This research is AI-generated and is not investment advice.

Research date
2026-10-30
Valuation & peersInput limits notedFair-value cells, peer multiples and the inputs behind the range

Valuation the research computed

Against the 2026-10-30 close of $30.52 (recorded)

Fundamentals reference date: 2026-06-28.

Fair value by discounted cash flow, at the cells this run nominated.

Bear
$12.30−60% vs close
Base
$18.30−40% vs close
Bull
$33.90+11% vs close

Implied by the median of 3 peer-median multiples: $35.01 (+14.7% vs close)

Peers: the 6 Liquid 100 names in Health Care that this run priced. Companies outside the Liquid 100 are not in the set.

The names: BMY, BSX, MDT, MRK, MRNA, VTRS.

Multiples against the peer group

Health Care · 6 companies in the group

  • Price to earnings (trailing twelve months)40.16×

    Peer median 20.39× · middle half 16.21× to 47.74× · 75th percentile of the group

  • Price to sales2.75×

    Peer median 3.15× · middle half 2.67× to 4.99× · 33rd percentile of the group

  • Price to book2.05×

    Peer median 3.99× · middle half 2.48× to 7.97× · 17th percentile of the group

  • Free cash flow yield6.28%

    Peer median 5.36% · middle half 4.5% to 6.89% · 67th percentile of the group

This run declares Enterprise value to EBITDA and computes no value for it, for this company or for its peer group.

Evidence limits: 7 valuation inputs required conservative handling: no full-year gross-profit line was filed; no full-year operating income was filed; another valuation input required conservative handling; depreciation and amortization were available but not used because this version does not compute an EV/EBITDA multiple.

Includes the currently displayed specialist or comparison, not every specialist. Dates and limitations remain attached.

Sagehood research is for general information. It is not individualized investment advice or a recommendation to buy or sell any security.

Pfizer (PFE) research | Sagehood